Evidera
Zaeem Khan is a seasoned professional in epidemiology and scientific affairs, currently serving as a Senior Research Associate at Thermo Fisher Scientific since March 2021. In this role, Zaeem provides scientific guidance on study design and execution while overseeing the development of essential scientific project deliverables for regulatory submission. Prior to this, Zaeem held various positions at ICON plc, contributing to clinical studies and strategic decision-making as an Epidemiologist and Associate Epidemiologist. Earlier experience includes a Research Assistant role at CAREX Canada and internships at the Public Health Surveillance Unit and the World Health Organization, where Zaeem focused on public health research and data analysis. Zaeem holds a Master of Public Health in Global Health from Simon Fraser University and a Bachelor of Science in Immunology & Infectious Diseases from the University of Alberta.
This person is not in any teams
This person is not in any offices
Evidera
1 followers
Evidera is a business within Pharmaceutical Product Development, LLC, (PPD) a leading global contract research organization (CRO), and is the preeminent provider of evidence-based solutions to demonstrate the real-world effectiveness, safety, and value of biopharmaceutical and biotechnology products from early development through loss of exclusivity. We provide integrated scientific expertise and global operational capabilities to help you generate the evidence needed to optimize the market access and commercial potential of your products. Evidera was acquired by PPD in 2016 and originally created in 2013 as an independent company under the ownership of Symphony Technology Group following the acquisition of long-standing health economics, outcomes research, market access, epidemiology, and data analytics practices from United BioSource Corporation (UBC). Evidera has over 30 years of leadership and experience and its legacy brands include MEDTAP, Caro Research, Abt Bio-Pharmaceutical Solutions, MetaWorks, Total Healthcare Group, and Archimedes.